Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by ...

Moderna Inc. lashed out at the US Food and Drug Administration for making it harder for companies to create new medicines, ...

Moderna (MRNA) stock fell 0.3% Friday despite beating Q4 revenue estimates at $678M and posting narrower loss of $2.11/share after FDA rejected flu vaccine review.

HealthDay News — In a major blow to vaccine development, the US Food and Drug Administration (FDA) said it will not review Moderna’s application for the first mRNA-based flu shot. Dr Vinay Prasad, the ...

In his confirmation hearings, Robert F. Kennedy Jr. told U.S. senators that he would not cut funding for vaccine research or change the nation's official vaccine recommendations. He did both.

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday ...

Moderna’s mRNA-1010 was expected to contribute $1 billion to the company’s coffers by 2028. That plan is now out the window after the FDA refused to even look at the application.

The stock soared more than 700% through 2020 and into the first weeks of 2021, and peak vaccine sales reached more than $18 billion for the 2022 full year. But, as demand for coronavirus vaccines ...

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global ...

Senior FDA official Vinay Prasad reportedly overrode his staff in deciding to reject Moderna's application for a new seasonal flu shot.

HHS Spokesman Andrew Nixon told The National News Desk via email that the FDA rejected Moderna’s application for filing because “the company refused to follow very clear FDA guidance from 2024 to test ...

Federal officials on Wednesday cast blame on Moderna as they stood by the Food and Drug Administration’s controversial ...